Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is an American commercial-stage biopharmaceutical enterprise focused on developing and commercializing gastrointestinal therapeutics for chronic GI diseases. The company commercializes Linzess (linaclotide), an oral prescription drug for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), in strategic partnership with AbbVie. Principal revenues derive from commercial sales profit shares, product royalties, and licensing milestone payments generated from Linzess sales across North America and international territories. Core end markets encompass gastroenterology specialty clinics, primary care physician networks, hospital health systems, and GI prescription patients in the United States and Japan. Ironwood Pharmaceuticals holds a market-leading position in the United States for prescription irritable bowel syndrome and chronic constipation treatments. The corporation is headquartered in Boston, Massachusetts, and its Class A common stock trades on the Nasdaq Global Select Market.
2 of the funds FundTelligence covers report a position in Ironwood Pharmaceuticals.
- Legal name
- Ironwood Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Ironwood Pharmaceuticals
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.2 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)